Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus - Komoroski, B; Vachharajani, N; Feng, Y (Clin Pharmacol Ther, 2009)
et al.